- Home
- FSBC vs STOK Comparison
FSBC vs STOK Comparison
Compare FSBC & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FSBC
- STOK
- Stock Information
- Founded
- FSBC 2002
- STOK 2014
- Country
- FSBC United States
- STOK United States
- Employees
- FSBC N/A
- STOK N/A
- Industry
- FSBC Banks
- STOK Biotechnology: Pharmaceutical Preparations
- Sector
- FSBC Finance
- STOK Health Care
- Exchange
- FSBC Nasdaq
- STOK Nasdaq
- Market Cap
- FSBC 650.2M
- STOK 556.7M
- IPO Year
- FSBC 2021
- STOK 2019
- Fundamental
- Price
- FSBC $30.06
- STOK $12.63
- Analyst Decision
- FSBC Buy
- STOK Strong Buy
- Analyst Count
- FSBC 4
- STOK 8
- Target Price
- FSBC $36.13
- STOK $21.83
- AVG Volume (30 Days)
- FSBC 44.9K
- STOK 867.9K
- Earning Date
- FSBC 01-27-2025
- STOK 03-24-2025
- Dividend Yield
- FSBC 2.69%
- STOK N/A
- EPS Growth
- FSBC N/A
- STOK N/A
- EPS
- FSBC 2.26
- STOK N/A
- Revenue
- FSBC $119,214,000.00
- STOK $16,742,999.00
- Revenue This Year
- FSBC N/A
- STOK $105.42
- Revenue Next Year
- FSBC $15.51
- STOK N/A
- P/E Ratio
- FSBC $13.38
- STOK N/A
- Revenue Growth
- FSBC 4.22
- STOK 81.08
- 52 Week Low
- FSBC $21.10
- STOK $4.09
- 52 Week High
- FSBC $35.13
- STOK $17.58
- Technical
- Relative Strength Index (RSI)
- FSBC 41.97
- STOK 68.53
- Support Level
- FSBC $28.95
- STOK $9.72
- Resistance Level
- FSBC $31.50
- STOK $11.11
- Average True Range (ATR)
- FSBC 0.96
- STOK 0.74
- MACD
- FSBC 0.08
- STOK 0.40
- Stochastic Oscillator
- FSBC 26.14
- STOK 98.48
About FSBC Five Star Bancorp
Five Star Bancorp is a California state-chartered non-member bank. The Company provides a broad range of banking products and services to small and medium-sized businesses, professionals, and individuals. It offers loan products like commercial real estate loans, commercial loans, commercial land and construction loans, and farmland loans and offers deposit products like checking accounts, savings accounts, money market accounts, and term certificate accounts.
About STOK Stoke Therapeutics Inc.
Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company primarily operates in the U.S.